NEJM publication implies Brianne Dressen withdrew from the trial. That's false.

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

A.R. Falsey, M.E. Sobieszczyk, I. Hirsch, S. Sproule, M.L. Robb, L. Corey, K.M. Neuzil, W. Hahn, J. Hunt, M.J. Mulligan, C. McEvoy, E. DeJesus, M. Hassman, S.J. Little, B.A. Pahud, A. Durbin, P. Pickrell, E.S. Daar, L. Bush, J. Solis, O.O. Carr,



SAFETY AND REACTOGENICITY

Unsolicited adverse events were recorded for all participants for 28 days after each dose of AZD1222 or placebo, and serious adverse events will be recorded from the time of signed informed consent through day 730. Medically attended adverse events and adverse events of special interest will be recorded from day 1 after the first dose through day 730. Reactogenicity was evaluated in the substudy group to investigate the incidence of solicited local and systemic adverse events

AZD1222 or pl

No new vaccine-related safety signals were identified, and solicited adverse events were mostly mild or moderate and were fewer in number after the second dose of AZD1222 than after the first. Results from this trial showed no evidence of increased overall risk of neurologic events,

- "**Withdrew**" is inaccurate
- I was **withdrawn**. It wasn't my choice.
- My crime? I suffered adverse events
- Adverse events that turned my life upside down

Source: Falsey et al. N Engl J Med. Sep 29, 2021.https://doi.org/10.1056/NEJMoa2105290

10 months COVID-19 vaccines vs 20 years of flu vaccines